NEW YORK(GenomeWeb) – Pfizer this week launched its Center of Excellence in Precision in Medicine (CEPM) in Chile. 

Efforts at the center will initially focus on validating new, more precise, and less invasive technologies for diagnosing cancer, and in addition to Pfizer's $14 million investment into the center, the Chilean Economic Development Agency (Corfo) is providing $7 million over four years. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.